Durasert continues to reduce recurrence of posterior segment uveitis through 12 months

A phase 3 trial of Durasert 3-year treatment for posterior segment uveitis showed a significant reduction in uveitis recurrence at 12 months, according to a press release from pSivida.

The study, which examined 153 patients with posterior segment uveitis, found 36.6% of patients treated with Durasert had a recurrence while 71.2% of those in the sham group experienced a recurrence. The trial previously showed a significant reduction in the recurrence of posterior segment uveitis through 6 months of treatment.

“We continue to receive highly positive feedback from specialists regarding Durasert 3 year for posterior segment uveitis, which bolsters our team’s confidence that there will be strong interest to treat patients dealing with this devastating disease, which is the third leading cause of blindness, pending a favorable regulatory review,” Nancy Lurker, pSivida president and CEO, said in the release.

pSivida is currently awaiting a decision on its new drug application for Durasert, which was submitted to the FDA in January.

A phase 3 trial of Durasert 3-year treatment for posterior segment uveitis showed a significant reduction in uveitis recurrence at 12 months, according to a press release from pSivida.

The study, which examined 153 patients with posterior segment uveitis, found 36.6% of patients treated with Durasert had a recurrence while 71.2% of those in the sham group experienced a recurrence. The trial previously showed a significant reduction in the recurrence of posterior segment uveitis through 6 months of treatment.

“We continue to receive highly positive feedback from specialists regarding Durasert 3 year for posterior segment uveitis, which bolsters our team’s confidence that there will be strong interest to treat patients dealing with this devastating disease, which is the third leading cause of blindness, pending a favorable regulatory review,” Nancy Lurker, pSivida president and CEO, said in the release.

pSivida is currently awaiting a decision on its new drug application for Durasert, which was submitted to the FDA in January.